Cetera Investment Advisers’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.31M Buy
25,760
+2,621
+11% +$216K ﹤0.01% 2277
2026
Q1
$1.83M Buy
23,139
+464
+2% +$37.5K ﹤0.01% 2356
2025
Q4
$1.86M Buy
22,675
+680
+3% +$52.6K ﹤0.01% 2273
2025
Q3
$1.54M Buy
21,995
+1,597
+8% +$108K ﹤0.01% 2398
2025
Q2
$1.31M Sell
20,398
-720
-3% -$44.6K ﹤0.01% 2156
2025
Q1
$1.34M Sell
21,118
-1,992
-9% -$134K ﹤0.01% 2036
2024
Q4
$1.54M Sell
23,110
-547
-2% -$37.7K ﹤0.01% 1847
2024
Q3
$1.65M Sell
23,657
-4,236
-15% -$293K ﹤0.01% 1763
2024
Q2
$1.81M Buy
27,893
+561
+2% +$35.5K ﹤0.01% 1644
2024
Q1
$1.77M Buy
27,332
+14,271
+109% +$929K ﹤0.01% 1641
2023
Q4
$860K Buy
13,061
+1,370
+12% +$79.7K 0.01% 1191
2023
Q3
$667K Buy
11,691
+758
+7% +$46.2K 0.01% 1274
2023
Q2
$670K Buy
10,933
+3,761
+52% +$235K 0.01% 1288
2023
Q1
$450K Buy
7,172
+1,683
+31% +$108K ﹤0.01% 1486
2022
Q4
$349K Buy
+5,489
New +$348K ﹤0.01% 1566

Other funds holding PBE

Cetera Investment Advisers's PBE Position: Q2 2026 in Review

Cetera Investment Advisers increased its Invesco Biotechnology & Genome ETF (PBE) stake by 11% in Q2 2026, buying an estimated $216K and bringing the position to 25,760 shares worth $2.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2277.

Cetera Investment Advisers first reported a position in PBE in Q4 2022 and has held it in 15 quarters since. 105 funds tracked by Wall St. Rank hold PBE as of Q2 2026.

  • Cetera Investment Advisers held 25,760 shares of Invesco Biotechnology & Genome ETF worth $2.31M as of Q2 2026.
  • Cetera Investment Advisers bought 2,621 Invesco Biotechnology & Genome ETF shares in Q2 2026, an estimated $216K.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #2277 holding.
  • Cetera Investment Advisers first reported a position in Invesco Biotechnology & Genome ETF in Q4 2022 and has held it in 15 quarters since.
  • 105 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.